key: cord-0797794-8luzi1gi
authors: Sweis, Auddie M.; Locke, Tran B.; Douglas, Jennifer E.; Lin, Theodore C.; Sweis, Brian M.; Civantos, Alyssa M.; Kennedy, David W.
title: Management of chronic rhinosinusitis with steroid nasal irrigations: a viable non‐surgical alternative in the COVID‐19 Era
date: 2020-06-22
journal: Int Forum Allergy Rhinol
DOI: 10.1002/alr.22646
sha: 62c12d17fae26ce0cd6620465aa883f8f7f0c750
doc_id: 797794
cord_uid: 8luzi1gi

BACKGROUND: High‐dose, high‐volume steroid nasal irrigations (NSI) have been incorporated into the medical management of recalcitrant CRS, primarily following surgical intervention. The objective of this study was to evaluate the role of NSI as a preoperative management and to identify the percentage of patients who ultimately underwent ESS for recalcitrant CRS despite being on NSI. METHODS: Retrospective chart review of patients presenting with CRS who underwent a trial of NSI for at least six weeks. Pre‐irrigation and post‐irrigation outcomes measured included Lund‐Mackay scores (LMS), SNOT‐22 scores, and whether or not the patient underwent ESS. RESULTS: Of the 90 patients who underwent NSI, 32 patients underwent ESS, while 58 patients had a significant enough improvement in symptoms to avoid ESS. The likelihood of decision for surgery did not differ between the mometasone and budesonide groups (p=0.3094), comorbid asthma status (p=0.3585), smoking status (p=0.2256), polyp status (p=0.7288), or history of prior ESS (p=0.5803). SNOT scores significantly improvement following NSI in the group of patients that did not go on to ESS (p<0.0001) and in the group that did (p<0.0001). LMS also improved following NSI, but this was only statistically significant in the patients that ultimately went on to ESS (p=0.0102). CONCLUSIONS: After a trial of NSI, 64.4% of patients with CRS no longer met candidacy for ESS and had a significant improvement in SNOT‐22 scores. This supports the use of nasal steroid irrigations in the medical management of CRS with and without surgical intervention and with and without nasal polyposis. This article is protected by copyright. All rights reserved

High-dose, high-volume nasal steroid irrigations (HVNSI) have been incorporated into the medical management of recalcitrant chronic rhinosinusitis (CRS) following surgical intervention, and have proven efficacy. 1 However, there has been limited data evaluating the effectiveness of HVNSI in patients prior to surgical intervention. In a pilot study, we retrospectively evaluated a group of patients who were candidates for ESS but pursued HVSI as an alternative therapy. This has become particularly valuable in the era of COVID-19, where outpatient clinical and operative volume has been reduced in the interest of protecting patients, staff, and surgeons. Saline irrigations, with or without the off-label addition of high dose topical steroids, have been shown to improve symptoms in patients with CRS as either the main modality of or in combination with other treatments. 1, 5 Currently, the impact of HVNSI on CRS patients is unknown with regard to limiting or delaying the need for surgical intervention. Traditionally, surgery is performed prior to the initiation HVNSI in order to maximize sinus access of topical therapy. In an institution where HVNSI is frequently prescribed for CRS and utilized prior to surgical intervention, we sought to identify the value of HVNSI in patients who were candidates for ESS.

A pilot study was approved by the University of Pennsylvania Institutional Review Board to evaluate patients with CRS cared for by one attending rhinologist over a nine year period. This was admittedly a highly heterogenous population with regard to disease type, severity, and other treatment modalities, but included patients with a diagnosis of CRSsNP or CRSwNP who completed 6 weeks of twice daily HVNSI (either mometasone or budesonide).

Overall, we found that patients found this therapy acceptable, and were willing to trial HVNSI in the interest of avoiding ESS. Ninety patients underwent HVNSI with budesonide or with mometasone. The group was heterogenous in regards to CRS phenotype, surgical history, medical co-morbidities, and social history ( Table 1 ). The majority of patients did not undergo ESS (64%), and notably this did not differ based on CRS phenotype, surgical history, medical co-morbidities, and social history. SNOT-22 scores significantly improved following HVNSI in all patients regardless of whether or not they went on to have ESS (p<0.0001) (Figure 1 ). Lund-Mackay improved following HVNSI, but this was only statistically significant in the patients that ultimately went on to ESS (p=0.0102).

While this pilot study represents a limited evaluation from which we must temper our general conclusions, the principle is valuable. This is particularly true in the setting of the COVID-19 pandemic, at which time outpatient clinical and surgical volume has been significantly reduced, and we are prioritizing non-surgical therapies for patients who might otherwise qualify with ESS. There has previously been a movement in the literature for early, upfront ESS in order to save patients from prolonged poor QOL, financial burden, and progression of symptoms, particularly in asthmatics. 6 However, the current study helps to demonstrate that patients with CRS who commit to at least 6 weeks of HVNSI stand to improve QOL outcome measures, a majority in whom it was significant enough that they no longer met ESS candidacy.

Further analysis showed that likelihood of proceeding to ESS did not differ between CRS phenotypes, raising the important point that patients with both CRSwNP and CRSsNP benefit from HVNSI. Importantly, likelihood of proceeding to ESS did not differ between patients with and without a history of ESS, suggesting that patients may benefit from further medical management with HVNSI rather than up front or early ESS if a patient is naïve to this regimen. Though not approved by the United States Food and Drug Administration (FDA), HVNSI have been investigated and overall appear safe for long-term use and their use should be reviewed with patients as such. 7, 8 Because of the lack of FDA approval, insurance coverage can be a limiting factor in accessibility of HVNSI. We find that use of a mail-order direct to consumer pharmacy limits cost for our patients.

Given the nature of the pilot study, our findings are limited, however, some CRS patients demonstrated a significant improvement in SNOT-22 scores when comparing preirrigation scores to post-irrigation scores. Our overall rate of patients going on to ESS despite an adequate trial of HVNSI was only 34%. This generally supports consideration of the use of HVNSI in patients with CRS regardless of polyp status or history of prior surgery.

Future studies must be aimed at providing prospective data with an effort at matching patients based on age, sex, medical co-morbidities, insurance status, and surgical history.

Additionally, comparing pre-operative quality of life measures in the context of HVNSI is necessary as this is known to impact decision for surgery. This is particularly important at a time when surgical intervention carries significant risks to the patient, staff, and surgeon due to the novel coronavirus, a risk that will not fully resolve once the surge has peaked. Table 1 

Corticosteroid nasal irrigations are more effective than simple sprays in a randomized double-blinded placebo-controlled trial for chronic rhinosinusitis after sinus surgery

When do the risks of repeated courses of corticosteroids exceed the risks of surgery?

Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis

Surgical versus medical interventions in CRS and nasal polyps: comparative evidence between medical and surgical efficacy

Nasal saline irrigations for the symptoms of chronic rhinosinusitis

Impact of medically recalcitrant chronic rhinosinusitis on incidence of asthma

Safety analysis of long-term budesonide nasal irrigations in patients with chronic rhinosinusitis post endoscopic sinus surgery

The effects of serum and urinary cortisol levels of topical intranasal irrigations with budesonide added to saline in patients with recurrent polyposis after endoscopic sinus surgery